CLINICAL TRIALS PROFILE FOR BYDUREON BCISE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Bydureon Bcise
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT04520490 ↗ | Brain Activation and Satiety in Children 2 | Recruiting | University of Washington | Phase 3 | 2021-01-28 | Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children. |
| New Combination | NCT04520490 ↗ | Brain Activation and Satiety in Children 2 | Recruiting | Seattle Children's Hospital | Phase 3 | 2021-01-28 | Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Bydureon Bcise
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00103935 ↗ | Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes | Completed | Eli Lilly and Company | Phase 2 | 2005-02-01 | Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus. |
| NCT00103935 ↗ | Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes | Completed | AstraZeneca | Phase 2 | 2005-02-01 | Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus. |
| NCT00308139 ↗ | Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) | Completed | AstraZeneca | Phase 3 | 2006-04-01 | A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications. |
| NCT00877890 ↗ | A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) | Completed | Eli Lilly and Company | Phase 3 | 2009-03-01 | This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability. |
| NCT00877890 ↗ | A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) | Completed | AstraZeneca | Phase 3 | 2009-03-01 | This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability. |
| NCT01089569 ↗ | Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine | Completed | International Diabetes Center at Park Nicollet | N/A | 2010-04-01 | The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin. |
| NCT01089569 ↗ | Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine | Completed | Sanofi | N/A | 2010-04-01 | The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Bydureon Bcise
Condition Name
Clinical Trial Locations for Bydureon Bcise
Trials by Country
Clinical Trial Progress for Bydureon Bcise
Clinical Trial Phase
Clinical Trial Sponsors for Bydureon Bcise
Sponsor Name
